Lexeo Therapeutics, Inc.
LXEO
$4.83
$0.173.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.07% | -25.97% | 12.09% | -38.85% | 2.05% |
| Total Depreciation and Amortization | 1.80% | -3.84% | 2.36% | 2.62% | 4.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -107.68% | 6.46% | -8.07% | 33.17% | 22.09% |
| Change in Net Operating Assets | -119.93% | 205.04% | -186.77% | 427.30% | -156.29% |
| Cash from Operations | -25.34% | 23.34% | -59.08% | 11.64% | -35.55% |
| Capital Expenditure | -- | -- | 100.00% | 61.03% | -15.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -350.42% | 116.67% | -- | 100.00% | 37.50% |
| Cash from Investing | -351.12% | 116.67% | -112,650.60% | 61.93% | -12.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.27% | -37.07% | -4.50% | -50.00% | 32.11% |
| Issuance of Common Stock | 46,958.24% | -97.31% | 16,082.05% | -99.41% | -92.49% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 663,172.73% | 111.34% | -34.72% | -124.74% | -99.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 207.57% | 95.00% | -579.28% | 10.55% | -127.28% |